• (-)-JQ1: A Rigorous BET Control Workflow

  2026-08-12

  (-)-JQ1 is an inactive JQ1 stereoisomer designed to separate BET bromodomain-dependent effects from vehicle, scaffold, and off-target responses. This practical workflow shows how to pair it with active JQ1, reporter assays, and cell-to-animal screening strategies for more defensible epigenetics and cancer biology research.

• Netarsudil: From ROCK Biology to Assay Design

  2026-08-11

  Netarsudil (AR-13324) is more than a ROCK inhibitor: it is a useful model for connecting cytoskeletal pharmacology with rational siRNA formulation. This article presents a decision-oriented framework for interpreting trabecular meshwork assays, nanoparticle studies, and formulation controls.

• Canagliflozin Hemihydrate: Research Workflow

  2026-08-11

  Build reproducible glucose transport and metabolic assays with Canagliflozin hemihydrate, a research-grade SGLT2 inhibitor suited to renal and diabetes mellitus research. A parallel yeast mTOR workflow helps distinguish glucose-transporter biology from nonspecific TOR-pathway effects.

• Trichostatin A (TSA) for Reliable Cell Assays

  2026-08-10

  Learn how Trichostatin A (TSA), SKU A8183, can improve the interpretation and reproducibility of cell viability, proliferation, and cytotoxicity experiments. This scenario-based guide covers mechanism, solvent compatibility, concentration selection, data interpretation, and practical vendor evaluation.

• Morin and the Energy Logic of Podocyte Protection

  2026-08-09

  Morin is emerging as more than a generic antioxidant: recent work links its protective effects in fructose-stressed podocytes to adenosine 5′-monophosphate deaminase activity and mitochondrial energy metabolism. This article translates that mechanism into practical assay strategy and translational decision-making.

• EZH2 Inhibition in HPV-Associated Cervical Cancer

  2026-08-07

  The reference study evaluates EPZ6438 and ZLD1039 as pharmacological strategies for suppressing HPV-associated cervical cancer, combining proliferation, apoptosis, cell-cycle, gene-expression, and preliminary in vivo readouts. Its main contribution is linking EZH2 inhibition with reduced HPV16 E6/E7 expression, restoration of p53 and Rb-associated tumor-suppressive signals, and epithelial marker expression, while identifying stronger activity of EPZ6438 in HPV-positive models.

• BET Bromodomain Inhibitor, (+)-JQ1: Optimizing Translational

  2026-08-07

  Bromodomain Inhibitor, (+)-JQ1 empowers researchers to dissect epigenetic regulation, apoptosis, and inflammation with precision, thanks to its potent and selective BET inhibition. This article delivers actionable workflows, troubleshooting, and the latest synergy insights for translational and disease-modeling applications.

• Topotecan as a Novel Topoisomerase I Inhibitor: Clinical Ins

  2026-08-06

  This review highlights the pharmacological innovation of topotecan, a water-soluble camptothecin analogue, as a topoisomerase I inhibitor with demonstrated clinical efficacy in solid tumors. The article discusses its unique mechanism, pharmacokinetics, toxicity profile, and implications for combination chemotherapy, particularly in comparison to established agents such as etoposide.

• Sumatriptan Succinate: Metabolic Pathways and Inflammation I

  2026-08-06

  Explore the advanced metabolism and anti-inflammatory mechanisms of Sumatriptan Succinate, a leading 5-HT1 receptor agonist. This article uncovers new experimental considerations crucial for migraine research, differentiating itself from standard protocol guides.

• MCL-1 Inhibitor A-1210477: Precision Tools for Cancer Apopto

  2026-08-05

  This article explores the mechanistic, experimental, and translational value of the MCL-1 inhibitor A-1210477, offering strategic guidance for researchers aiming to dissect cancer cell survival pathways. Blending evidence-based insights with practical workflow advice, it clarifies how selective MCL-1 inhibition can transform apoptosis research and the rational design of targeted cancer therapies.

• Applied Workflows with Recombinant Human IL-15 in Immunology

  2026-08-05

  Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) enables precise, reproducible activation and expansion of T and NK cells, empowering advanced immune response assays and neuroimmune research. This guide translates bench protocols, troubleshooting strategies, and cross-domain insights for high-impact immunology labs.

• PPARγ Activation Modulates Macrophage Polarization in IBD

  2026-08-04

  This study demonstrates that PPARγ activation, specifically via pioglitazone, regulates M1/M2 macrophage polarization and attenuates inflammatory bowel disease (IBD) through the STAT-1/STAT-6 pathway. The findings highlight a mechanistic link between nuclear receptor signaling and immune cell function, providing new insights for research on inflammation and metabolic disorders.

• Melittin as a Bioactive Peptide in Signal Transduction Modul

  2026-08-04

  Melittin offers precise control over GPCR signaling, uniquely enabling researchers to dissect Gs and Gi protein pathways in cancer biology and apoptosis models. This article provides experimental workflow guidance, troubleshooting insights, and translates breakthrough findings from glioblastoma research into actionable protocols.

• Puromycin dihydrochloride: Technical Use and Protocol Setup

  2026-08-03

  Puromycin dihydrochloride is an aminonucleoside antibiotic widely used for rapid selection of pac gene-expressing cell lines and for dissecting protein synthesis in molecular biology. It is optimal for projects requiring robust selection pressure or ribosome function analysis, but is not suited for reversible translation inhibition or applications with uncontrolled cytotoxicity.

• Intranasal Sumatriptan as First-Line Pediatric Migraine Ther

  2026-08-03

  A recent single-center retrospective study demonstrates that intranasal sumatriptan, a selective 5-HT1 receptor agonist, is a feasible and potentially effective first-line treatment for pediatric migraine in the emergency department. This pathway reduced intravenous intervention rates, shortened ED stays, and lowered associated costs, highlighting an evidence-backed strategy for acute pediatric migraine management.

16552 records 1/1104 page Next 12345 下5页 Last page